↓ Skip to main content

A randomized, comparative study of dual therapy (doxycycline–rifampin) versus triple therapy (doxycycline–rifampin–levofloxacin) for treating acute/subacute brucellosis

Overview of attention for article published in Brazilian Journal of Infectious Diseases, May 2016
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
25 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A randomized, comparative study of dual therapy (doxycycline–rifampin) versus triple therapy (doxycycline–rifampin–levofloxacin) for treating acute/subacute brucellosis
Published in
Brazilian Journal of Infectious Diseases, May 2016
DOI 10.1016/j.bjid.2016.02.004
Pubmed ID
Authors

Ahmad Hasanain, Reem Mahdy, Asmaa Mohamed, Mostafa Ali

Abstract

The aim of this study was to compare both the efficacy and safety profile of the WHO-recommended, dual therapy (doxycycline-rifampin) to a quinolone-based, triple therapy (doxycycline-rifampin-levofloxacin) for treating acute/subacute brucellosis. We studied 107 consecutive, naïve patients with acute/subacute brucellosis admitted to Assiut University Hospital. Patients were randomly allocated to receive the dual therapy of doxycycline-rifampin (group-A) or to receive the triple therapy of doxycycline-rifampin-levofloxacin (group-B). Acute/subacute brucellosis was diagnosed based on the presence of: (1) contact with animals or fresh animal products, (2) suggestive clinical manifestations of less than one-year duration, and (3) positive antibody titer (1:160) by standard tube agglutination test. There was no significant difference between the two groups regarding their demographic data. Fever was the most frequent manifestation (96.3%). Epigastric pain was the most frequent adverse effect of treatment (12.1%). Group-A patients had a significantly higher relapse rate compared to group-B patients (22.6% versus 9.3%, p-value=0.01). The rate of treatment adverse effects was higher among group-B patients, although not reaching statistical significance (20.4% versus 11.3%, p-value=0.059). Adding levofloxacin to the dual therapy for acute/subacute brucellosis (doxycycline-rifampin) may increase its efficacy in terms of lowering the relapse rate of the disease. Further, larger scale studies are needed before considering modifying the standard, dual therapy for brucellosis.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Kenya 1 4%
Unknown 24 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 20%
Student > Bachelor 4 16%
Researcher 2 8%
Professor > Associate Professor 2 8%
Student > Doctoral Student 1 4%
Other 5 20%
Unknown 6 24%
Readers by discipline Count As %
Medicine and Dentistry 7 28%
Veterinary Science and Veterinary Medicine 3 12%
Pharmacology, Toxicology and Pharmaceutical Science 2 8%
Environmental Science 1 4%
Biochemistry, Genetics and Molecular Biology 1 4%
Other 4 16%
Unknown 7 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 July 2016.
All research outputs
#10,725,019
of 13,479,745 outputs
Outputs from Brazilian Journal of Infectious Diseases
#220
of 371 outputs
Outputs of similar age
#183,720
of 262,694 outputs
Outputs of similar age from Brazilian Journal of Infectious Diseases
#3
of 4 outputs
Altmetric has tracked 13,479,745 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 371 research outputs from this source. They receive a mean Attention Score of 2.0. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 262,694 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.